Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec 7;16(12):e0260568.
doi: 10.1371/journal.pone.0260568. eCollection 2021.

Prevalence and predictors of Post-Acute COVID-19 Syndrome (PACS) after hospital discharge: A cohort study with 4 months median follow-up

Imad M Tleyjeh  1   2   3   4 , Basema Saddik  5   6 , Nourah AlSwaidan  7 , Ahmed AlAnazi  7 , Rakhee K Ramakrishnan  6 , Deema Alhazmi  7 , Ahmad Aloufi  7 , Fahad AlSumait  7 , Elie Berbari  3 , Rabih Halwani  5   6   8
Affiliations

Prevalence and predictors of Post-Acute COVID-19 Syndrome (PACS) after hospital discharge: A cohort study with 4 months median follow-up

Imad M Tleyjeh et al. PLoS One. .

Abstract

Background: Post-acute COVID-19 syndrome (PACS) is an emerging healthcare burden. The risk factors associated with PACS remain largely unclear. The aim of this study was to evaluate the frequency of new or persistent symptoms in COVID-19 patients post hospital discharge and identify associated risk factors.

Methods: Our prospective cohort comprised of PCR-confirmed COVID-19 patients admitted to King Fahad Medical City, Riyadh, Saudi Arabia between May and July 2020. The patients were interviewed through phone calls by trained physicians from 6 weeks up to 6 months post hospital discharge. Multivariate Cox proportional hazards and logistic regression models were used to examine for predictors associated with persistence of symptoms and non-return to baseline health.

Results: 222 COVID-19 patients responded to follow-up phone interviews after a median of 122 days post discharge. The majority of patients were men (77%) with mean age of 52.47 (± 13.95) years. 56.3% of patients complained of persistent symptoms; 66 (29.7%) experiencing them for >21 days and 64 (28.8%) reporting not having returned to their baseline health. Furthermore, 39 patients (17.6%) reported visiting an emergency room post discharge for COVID-19-related symptoms while 16 (7.2%) had required re-hospitalization. Shortness of breath (40.1%), cough (27.5%) and fatigue (29.7%) were the most frequently reported symptoms at follow-up. After multivariable adjustments, female gender, pre-existing hypertension and length of hospital stay were associated with an increased risk of new or persistent symptoms. Age, pre-existing lung disease and emergency room visits increased the likelihood of not fully recovering from acute COVID-19. Patients who were treated with interferon β-1b based triple antiviral therapy during hospital stay were less likely to experience new or persistent symptoms and more likely to return to their baseline health.

Conclusions: COVID-19 survivors continued to suffer from dyspnea, cough and fatigue at 4 months post hospital discharge. Several risk factors could predict which patients are more likely to experience PACS and may benefit from individualized follow-up and rehabilitation programs.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Flow diagram of COVID-19 patients hospitalized at KFMC between May and July, 2020.
Fig 2
Fig 2. Prevalence of symptoms at presentation and follow-up (N = 125).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, et al.. Post-acute COVID-19 syndrome. Nature medicine. 2021;27(4):601–15. doi: 10.1038/s41591-021-01283-z - DOI - PMC - PubMed
    1. Zhang Y, Geng X, Tan Y, Li Q, Xu C, Xu J, et al.. New understanding of the damage of SARS-CoV-2 infection outside the respiratory system. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2020;127:110195. doi: 10.1016/j.biopha.2020.110195 - DOI - PMC - PubMed
    1. Bai Y, Yao L, Wei T, Tian F, Jin DY, Chen L, et al.. Presumed Asymptomatic Carrier Transmission of COVID-19. Jama. 2020;323(14):1406–7. doi: 10.1001/jama.2020.2565 - DOI - PMC - PubMed
    1. Carfì A, Bernabei R, Landi F. Persistent Symptoms in Patients After Acute COVID-19. Jama. 2020;324(6):603–5. doi: 10.1001/jama.2020.12603 - DOI - PMC - PubMed
    1. Nishiura H, Kobayashi T, Miyama T, Suzuki A, Jung SM, Hayashi K, et al.. Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19). International journal of infectious diseases: IJID: official publication of the International Society for Infectious Diseases. 2020;94:154–5. doi: 10.1016/j.jebdp.2020.101499 - DOI - PMC - PubMed

MeSH terms